High-dose chemotherapy with autologous hematopoietic stem cell transplantation for high-risk primary breast cancer

Journal of the National Cancer Institute - Monographs

Volumn 2015, Issue 51, 2015, Pages 70-75

  Pedrazzoli, Paolo ^a   Martino, Massimo ^b   Delfanti, Sara ^a   Generali, Daniele ^c   Rosti, Giovanni ^d   Bregni, Marco ^e   Lanza, Francesco ^c  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^c CREMONA HOSPITAL   (Italy)

^d OSPEDALE CA FONCELLO   (Italy)

^e OSPEDALE DI CIRCOLO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER REGRESSION; DRUG EFFICACY; DRUG MEGADOSE; HIGH RISK PATIENT; HUMAN; META ANALYSIS (TOPIC); OVERALL SURVIVAL; PERSONALIZED MEDICINE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY TUMOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; TRIPLE NEGATIVE BREAST CANCER; AUTOTRANSPLANTATION; BREAST NEOPLASMS; DOSE RESPONSE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MULTIMODALITY CANCER THERAPY; PROCEDURES; RISK FACTOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84932640294     PISSN: 10526773     EISSN: 17456614     Source Type: Book Series    
DOI: 10.1093/jncimonographs/lgv010     Document Type: Article

References (72)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin. 2009;59(4):225-249.
2. Malvezzi M, Bertuccio P, Levi F, et al. European cancer mortality predictions for the year 2013. Ann Oncol. 2013;24(3):792-800.
3. American Cancer Society. Cancer Facts & Figures, 2013. Atlanta, GA: American Cancer Society; 2013.
4. National Compreshensive Cancer Network. NCCN Breast Cancer Version. 3. 2013. http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf. Accessed July13, 2013.
5. Norton L. A Gompertzian model of human breast cancer growth. Cancer Res. 1988;48(24 pt 1):7067-7071.
6. Hryniuk W, Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol. 1986;4(8):1162-1170.
7. Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med. 1981;304(1):10-15.
8. Peters WP, Ross M, Vredenburgh JJ, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol. 1993;11(6):1132-1143.
9. Gianni AM, Siena S, Bregni M, et al. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. J Clin Oncol. 1997;15(6):2312-2321.
10. Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol. 2000;18(6):1360-1377.
11. Pedrazzoli P, Ferrante P, Kulekci A, et al. Autologous hematopoietic stem cell transplantation for breast cancer in Europe: critical evaluation of data from the European Group for Blood and Marrow Transplantation (EBMT) Registry 1990-1999. Bone Marrow Transplant. 2003;32(5):489-494.
12. Pedrazzoli P, Rosti G, Secondino S, et al. High-dose chemotherapy with autologous hematopoietic stem cell support for solid tumors in adults. Semin Hematol. 2007;44(4):286-295.
13. Nitz UA, Mohrmann S, Fischer J, et al. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial. Lancet. 2005;366(9501):1935-1944.
14. Rodenhuis S, Bontenbal M, van Hoesel QG, et al. Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer. Ann Oncol. 2006;17(4):588-596.
15. Berry DA, Ueno NT, Johnson MM, et al. High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol. 2011;29(24):3214-3223.
16. De Giorgi U, Amadori D. Dose intensification in hormone receptor-negative and/or human epidermal growth factor receptor 2-negative high-risk primary breast cancer. J Clin Oncol. 2012;30(7):758.
17. Moroni M. High-dose chemotherapy as adjuvant therapy in breast cancer: could there be a survival benefit? J Clin Oncol. 2012;30(7):759.
18. Wang J, Zhang Q, Zhou R, et al. High-dose chemotherapy followed by autologous stem cell transplantation as a first-line therapy for high-risk primary breast cancer: a meta-analysis. PLoS One. 2012;7(3):e33388.
19. Martino M, Bottini A, Rosti G, et al. Critical issues on high-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in breast cancer patients. Expert Opin Biol Ther. 2012;12(11):1505-1515.
20. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003;21(8):1431-1439.
21. Hudis C, Citron M, Berry D, et al. Five year follow-up of INT C9741: dosedense chemotherapy is safe and effective. Breast Cancer Res Treat. 2005; 94(suppl):S20, abstr 41.
22. Moebus V, Jackisch C, Lueck HJ, et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Clin Oncol. 2010;28(17):2874-2880.
23. Eder JP, Antman K, Peters W, et al. High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. J Clin Oncol. 1986;4(11):1592-1597.
24. Hortobagyi GN, Buzdar AU, Theriault RL, et al. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst. 2000;92(3):225-233.
25. Rodenhuis S, Richel DJ, van der Wall E, et al. Randomised trial of highdose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet. 1998;352(9127):515-521.
26. Tallman MS, Gray R, Robert NJ, et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med. 2003;349(1):17-26.
27. Peters WP, Rosner GL, Vredenburgh JJ, et al. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol. 2005;23(10):2191-2200.
28. Gianni A, Bonadonna G, Michelangelo Cooperative Group. Five-year results of the randomized clinical trial comparing standard versus high-dose myeloablative chemotherapy in the adjuvant treatment of breast cancer with > 3 positive nodes (LN). Proc Am Soc Clin Oncol. 2001;20:21a, (abstr 80).
29. Zander AR, Kröger N, Schmoor C, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J Clin Oncol. 2004;22(12):2273-2283.
30. Coombes RC, Howell A, Emson M, et al. High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial. Ann Oncol. 2005;16(5):726-734.
31. Tokuda Y, Tajima T, Narabayashi M, et al. Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer: Japan Clinical Oncology Group study, JCOG 9208. Cancer Sci. 2008;99(1):145-151.
32. Bergh J, Wiklund T, Erikstein B, et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet. 2000;356(9239):1384-1391.
33. Roche H, Viens P, Biron P, et al. High-dose chemotherapy for breast cancer: the French PEGASE experience. Cancer Control. 2003;10(1):42-47.
34. Leonard RC, Lind M, Twelves C, et al. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. J Natl Cancer Inst. 2004;96(14):1076-1083.
35. Basser RL, O'Neill A, Martinelli G, et al. Multi cycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study group Trial 15-95. J. Clin. Oncol. 2006;24(3):370-378.
36. Moore HC, Green SJ, Gralow JR, et al. Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623. J Clin Oncol. 2007;25(13):1677-1682.
37. Gluz O, Nitz UA, Harbeck N, et al. Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial. Ann Oncol. 2008;19(5):861-870.
38. Marino P, Roché H, Moatti JP, et al. High-dose chemotherapy for patients with high-risk breast cancer: a clinical and economic assessment using a qualityadjusted survival analysis. Am J Clin Oncol. 2008;31(2):117-124.
39. Siena S, Bregni M, Di Nicola M, et al. Durability of hematopoiesis following autografting with peripheral blood hematopoietic progenitors. Ann Oncol. 1994;5(10):935-941.
40. Körbling M, Fliedner TM. The evolution of clinical peripheral blood stem cell transplantation. Bone Marrow Transplant. 1996;17(5):675-678.
41. Antman KH, Rowlings PA, Vaughan WP, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol. 1997;15(5):1870-1879.
42. Berry DA. Reply to Moroni M and De Giorgi U, et al. J Clin Oncol. 2012;30(7):759-760.
43. Bengala C, Zamagni C, Pedrazzoli P, et al. Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study. Br J Cancer. 2006;94(7):1016-1020.
44. Leoncini O, Da Prada GA, Pedrazzoli P. Costs of autologous stem-cell transplantation in solid tumours. Ann Oncol. 2001;12(1):131.
45. Barosi G, Marchetti M, Alessandrino P, et al. A model for analysing the cost of autologous peripheral blood progenitor cell (PBPC) transplantation. Bone Marrow Transplant. 1999;23(7):719-725.
46. Ferrara F, Izzo T, Criscuolo C, et al. Comparison of fixed dose pegfilgrastim and daily filgrastim after autologous stem cell transplantation in patients with multiple myeloma autografted on a outpatient basis. Hematol Oncol. 2011;29(3):139-143.
47. Morabito F, Martino M, Stelitano C, et al. Feasibility of a mixed inpatientoutpatient model of peripheral blood stem cell transplantation for multiple myeloma. Haematologica. 2002;87(11):1192-1199.
48. Morabito F, Irrera G, Oliva E, et al. Infectious complications in breast cancer patients undergoing peripheral blood stem cell transplantation: a single center retrospective analysis towards outpatient strategy. Bone Marrow Transplant. 2001;28(9):883-888.
49. Meisenberg BR, Ferran K, Hollenbach K, et al. Reduced charges and costs associated with outpatient autologous stem cell transplantation. Bone Marrow Transplant. 1998;21(9):927-932.
50. Hryniuk W, Frei E 3rd, Wright FA. A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: summation dose-intensity. J Clin Oncol. 1998;16(9):3137-3147.
51. Hortobagyi GN. What is the role of high-dose chemotherapy in the era of targeted therapies? J Clin Oncol. 2004;22(12):2263-2266.
52. Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352(22):2302-2313.
53. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21(6):976-983.
54. Nieto Y, Nawaz S, Jones RB, et al. Prognostic model for relapse after highdose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. J Clin Oncol. 2002;20(3):707-718.
55. Burstein HJ. Avastin for breast cancer, 2005-2011: requiescat in pacem? J Natl Compr Canc Netw. 2011;9(12):1321-1323.
56. O'Shaughnessy J, Schwartzberg LS, Danso MA, et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol. 2011;29(15 suppl):1007.
57. Elfenbein GJ. Stem-cell transplantation for high-risk breast cancer. N Engl J Med. 2003;349(1):80-82.
58. Sargent DJ, Wieand HS, Haller DG, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2005;23(34):8664-8670.
59. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343-2351.
60. Chan A, Miles DW, Pivot X. Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer. Ann Oncol. 2010;21(12):2305-2315.
61. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25-32.
62. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renalcell carcinoma. N Engl J Med. 2007;356(2):125-134.
63. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359(17):1757-1765.
64. Diallo-Danebrock R, Ting E, Gluz O, et al. Protein expression profiling in highrisk breast cancer patients treated with high-dose or conventional dosedense chemotherapy. Clin Cancer Res. 2007;13(2 pt 1):488-497.
65. Bonilla L, Ben-Aharon I, Vidal L, et al. Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. J Natl Cancer Inst. 2010;102(24):1845-1854.
66. Baird RD, Caldas C. Genetic heterogeneity in breast cancer: the road to personalized medicine? BMC Med. 2013;11:151.
67. Crown J, Wassherheit C, Hakes T, et al. Rapid delivery of multiple high-dose chemotherapy courses with granulocyte colony-stimulating factor and peripheral blood-derived hematopoietic progenitor cells. J Natl Cancer Inst. 1992;84(24):1935-1936.
68. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stemcell transplantation for multiple myeloma. N Engl J Med. 2003;349(26):2495-2502.
69. Simonelli M, Rosti G, Banna GL, Pedrazzoli P. Intensified chemotherapy with stem-cell rescue in germ-cell tumors. Ann Oncol. 2012;23(4):815-822.
70. Pedrazzoli P, Martinelli G, Gianni AM, et al.; of Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule staminali emopoietiche e terapia cellulare (GITMO)-Sezione Tumori Solidi. Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell support for high-risk primary breast cancer: results from the Italian national registry. Biol Blood Marrow Transplant. 2014;20(4):501-506.
71. Nieto Y, Shpall EJ. High-dose chemotherapy for high-risk primary and metastatic breast cancer: is another look warranted? Curr Opin Oncol. 2009;21(2):150-157.
72. Gluz O, Liedtke C, Gottschalk N, et al. Triple-negative breast cancer-current status and future directions. Ann Oncol. 2009;20(12):1913-1927.